- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02613923
A Sleep Intervention to Improve Outcomes Among Women at High Risk of Breast Cancer
A Pilot Sleep Intervention to Improve Outcomes Among Women at High Risk of Breast Cancer
Participants are asked to participate in a research study of the effect of a sleep intervention on improving sleep habits and reducing their risk of breast cancer.
Participants are asked to participate in this research study because they have been identified as being at higher than average risk of developing breast cancer.
The purpose of this study is to compare women who get a sleep intervention to women who do not get a sleep intervention. This study team will compare these two groups of women to see if the sleep intervention improves their sleep and if it lowers markers of inflammation that have been associated with an increased risk of breast cancer.
Visão geral do estudo
Status
Condições
Descrição detalhada
Objective 1: To test the effectiveness of the GO! To Sleep program at improving the sleep duration and sleep quality in women at high risk of breast cancer.
Objective 2: To test the effectiveness of improvements in sleep quality and/or duration due to the GO! To Sleep program on biomarkers of inflammation in women at high risk of breast cancer.
Objective 3: To evaluate the effectiveness of improvements in health-related quality of life after the GO! To Sleep in women at high risk of breast cancer.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44106
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Women at high risk of breast cancer due to one or more of the following:
- Carry deleterious mutations in the BRCA1, BRCA2, PTEN, TP53, STK11, or CDH1 genes
- Previous diagnosis of lobular carcinoma in situ (LCIS), atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH)
- Lifetime risk of 20% or greater as calculated by the National Cancer Institute (NCI) Breast Cancer Risk Assessment Tool or the Tyrer-Cuzick IBIS Risk Assessment Tool
- Ability to access the internet and watch videos online.
- Valid email address.
- Self-reported sleep duration of 6 hours per night or less
Exclusion Criteria:
- Previous diagnosis of cancer.
- Lack of ability to read and converse in English.
- Lack of ability to give informed consent.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: GO! To Sleep
Participants in the intervention group will be provided with a code and website address to participate in this program.
This program includes reminder emails and is 6 weeks in duration.
Participants will be given a blood draw to measure biomarkers.
|
Controlled sleep intervention.
Provide online education and reminder emails on improving sleep behavior
blood sample measured for stress and sleep markers
Outros nomes:
Assessment of sleep quality.
This is a continuous measure from 0 (best) to 21 (worst).
Sleep duration will be obtained directly from responses.
|
Comparador Ativo: informational control
Participants in the control group will receive weekly emails with sleep information and the health benefits of sleep for 6 weeks.Participants will be given a blood draw to measure biomarkers.
|
blood sample measured for stress and sleep markers
Outros nomes:
Assessment of sleep quality.
This is a continuous measure from 0 (best) to 21 (worst).
Sleep duration will be obtained directly from responses.
Participants will receive weekly emails on the health benefits of sleep for 6 weeks
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Difference in Change in Pittsburgh Sleep Quality Index (PSQI) score between groups
Prazo: Change from baseline to post intervention, around 8 weeks after baseline
|
Sleep quality will be measured by the PSQI which is a continuous measure from 0 (best) to 21 (worst)
|
Change from baseline to post intervention, around 8 weeks after baseline
|
Difference in change in Insomnia Severity Index (ISI) score between groups
Prazo: Change from baseline to post intervention, around 8 weeks after baseline
|
Sleep quality will be measured with the insomnia severity index (ISI).
A validated instrument for sleep quality
|
Change from baseline to post intervention, around 8 weeks after baseline
|
Difference in change in sleep duration between groups
Prazo: Change from baseline to post intervention, around 8 weeks after baseline
|
Sleep duration will be obtained by self-report from responses to the PSQI
|
Change from baseline to post intervention, around 8 weeks after baseline
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Difference in change of SF-12 score from baseline to post-intervention between groups
Prazo: Change from baseline to 6 months post intervention
|
The effectiveness of changing health-related quality of life after the GO!
To Sleep program will he measured with the self-reported survey SF-12
|
Change from baseline to 6 months post intervention
|
Correlation of joint changes in biomarker levels with PSQI and ISI
Prazo: Change from baseline to 6 months post intervention
|
This study will correlate the joint changes in biomarker level with the changes in sleep quality and sleep duration
|
Change from baseline to 6 months post intervention
|
Difference in Change in Pittsburgh Sleep Quality Index (PSQI) score between groups
Prazo: Change from baseline to 6 months post intervention
|
Long term sleep quality will be measured by the PSQI which is a continuous measure from 0 (best) to 21 (worst)
|
Change from baseline to 6 months post intervention
|
Difference in change in Insomnia Severity Index (ISI) score between groups
Prazo: Change from baseline to 6 months post intervention
|
Sleep quality will be measured with the insomnia severity index (ISI).
A validated instrument for sleep quality
|
Change from baseline to 6 months post intervention
|
Difference in change in sleep duration between groups
Prazo: Change from baseline to 6 months post intervention
|
Sleep duration will be obtained by self-report from responses to the PSQI
|
Change from baseline to 6 months post intervention
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Cheryl Thompson, PhD, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CASE6114
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Câncer de mama
-
Turku University HospitalLounais-Suomen SyöpäyhdistysAinda não está recrutandoSobrevivente de cancerFinlândia
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RetiradoSobrevivente de cancerEstados Unidos
-
University of Alabama at BirminghamNational Cancer Institute (NCI); Auburn UniversityConcluído
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos, Guam
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); National Institute of Mental Health (NIMH)ConcluídoSobrevivente de cancerEstados Unidos
-
Masonic Cancer Center, University of MinnesotaConcluídoSobrevivente de cancerEstados Unidos
-
University of New MexicoNew Mexico State University; University of New Mexico Cancer CenterConcluído
-
Ohio State University Comprehensive Cancer CenterConcluídoSobrevivente de cancerEstados Unidos
-
Abramson Cancer Center of the University of PennsylvaniaConcluídoPlano de cuidados de sobrevivência LIVESTRONG: coleta contínua de dados e pesquisa de acompanhamentoPaciente com cancerEstados Unidos
Ensaios clínicos em GO! To Sleep
-
University of MiamiThe Community Foundation of BrowardConcluído
-
Boise State UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institutes...ConcluídoMenor de idade bebendoEstados Unidos
-
Esslingen University of Applied SciencesFederal Ministry of Health, GermanyConcluídoConsumo de álcoolAlemanha
-
University of CalgaryCanadian Diabetes Association; Becton, Dickinson and Company; LifeScan CanadaConcluídoHipoglicemia | Diabetes mellitus tipo 1Canadá
-
VA Office of Research and DevelopmentEmory UniversityConcluído
-
VA Office of Research and DevelopmentConcluído
-
Neurovalens Ltd.Clinical Trial MentorsRetiradoTEPT | Insônia | Distúrbios de sono
-
Taipei Medical University Shuang Ho HospitalCase Western Reserve UniversityRecrutamentoAVC, Agudo | Distúrbios Respiratórios do Sono | Arquitetura do SonoTaiwan